• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quadrivalent influenza vaccine efficacious in children

bys25qthea
December 19, 2013
in Chronic Disease, Infectious Disease, Pediatrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Quadrivalent influenza vaccine (QIV) was found to have efficacy of approximately 60% in protecting children from influenza. 

2. QIV protection was more efficacious against moderate-to-severe influenza, with efficacy over 70%. Seroprotection rates after vaccination was over 95% for all four strains. 

Evidence Rating Level: 1 (Excellent)       

Study Rundown: This phase 3 trial demonstrated the safety and efficacy of quadrivalent influenza vaccine (QIV) in children 3 to 8 years old. In this study, QIV was found to be approximately 60% effective against influenza infection of any severity, and more than 70% effective against moderate-to-severe influenza infections, thus highlighting the efficacy in reducing clinically significant events. The study results are adequately powered with more than 5000 children enrolled in three parts of the world. Follow up rate was also high, with 95% of samples from children with suspected cases obtained and analyzed. The current study analyzed only one flu season. It did not address whether this quadrivalent vaccine is any more advantageous than the more widely used trivalent vaccine, as there were only 2 cases of B/Yamagata influenza. A quadrivalent vaccine may be of greater value during seasons in which both B lineages are circulating, or if there is a shift from one lineage to another during the same season. Future studies are needed to address this question.

The study was sponsored by GlaxoSmithKline. The sponsor was involved in all stages of the study conduct and analyses of data.

Click to read the study, published today in NEJM

RELATED REPORTS

Influenza is associated with an increased odds of Parkinson Disease diagnosis after 10 years

Antiviral agents such as zanamivir and baloxavir are associated with improved time to symptom alleviation for seasonal influenza

Maternal influenza vaccine during pregnancy not linked to adverse early childhood outcomes

Click to read an accompanying editorial in NEJM

Relevant Reading: Influenza and the Rates of Hospitalization for Respiratory Disease among Infants and Young Children

In-Depth [randomized controlled trial]: This study assessed the safety and efficacy of quadrivalent influenza vaccine (QIV) in children aged 3 to 8. The vaccine contained the hemagglutinin antigens from the following four strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Children were assigned in a 1:1 ratio to either receive QIV or hepatitis A vaccine as control. Primary end point was influenza A or B confirmed by rt-PCR. Secondary end point was rt-PCR confirmed, moderate-to-severe influenza.

In the total vaccinated cohort, 62 children in the QIV group (2.4%) and 148 in the control group (5.7%) had rt-PCR-confirmed influenza, reflecting a vaccine efficacy of 59.3% (95% confidence interval [CI], 45.2 to 69.7). In the per-protocol cohort, 58 children in the QIV group (2.4%) and 128 in the control group (5.3%) had rt-PCR-confirmed influenza, reflecting a vaccine efficacy of 55.4% (95% CI, 39.1 to 67.3). The vaccine had higher efficacies against moderate-to-severe influenza, with efficacy of 74.2% (97.5% CI, 51.5 to 86.2) in the total vaccinated cohort and 73.1% (97.5% CI, 47.1 to 86.3) in the per-protocol cohort.

In an immunogenicity analysis, seroprotection rates against each strain was more than 95% after vaccination. At 6 months post immunization, seroprotection rates were higher than 90% against A/H3N2 and B/Yamagata, and higher than 80% against A/H1N1 and B/Victoria. Safety end points did not differ between the QIV group and the control group.

By Xiaozhou Liu and Xu Gao 

More from this author: Nivolumab plus ipilimumab shows promise for metastatic melanoma, Prophylactic platelet transfusions prevent bleeding in hematologic cancers, Azithromycin is not associated with increased cardiovascular death in low-risk groups, Health education module reduces parasitic infections, New chemotherapy precludes the need for radiotherapy in primary mediastinal B-cell lymphoma.

©2012-2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: immunizationinfluenzaInfluenza vaccine
Previous Post

SSRI use during pregnancy not linked to increased risk of autism

Next Post

Updated JNC 8 guidelines for antihypertensive drugs released

RelatedReports

Influenza vaccine not associated with increased risk of epilepsy in children
Infectious Disease

Influenza is associated with an increased odds of Parkinson Disease diagnosis after 10 years

October 26, 2021
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Emergency

Antiviral agents such as zanamivir and baloxavir are associated with improved time to symptom alleviation for seasonal influenza

August 16, 2021
AAP guidelines for pneumococcal vaccination in high-risk groups released
Chronic Disease

Maternal influenza vaccine during pregnancy not linked to adverse early childhood outcomes

June 17, 2021
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Success rates and timelines of recently studied viral vaccine candidates

December 7, 2020
Next Post
Low diastolic blood pressure associated with higher mortality in chronic kidney disease

Updated JNC 8 guidelines for antihypertensive drugs released

Periodontitis therapy not improving HbA1C levels in type II diabetes patients

Periodontitis therapy not improving HbA1C levels in type II diabetes patients

Home visits in Ghana improve neonatal mortality

7% hypertonic saline does not improve clinical outcomes for acute bronchiolitis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Prior syncope presentation not associated with increased risk of motor vehicle collision
  • Baricitinib reduces mortality risk in patients hospitalized with COVID-19
  • Postoperative and nonoperative atrial fibrillation have a similar risk of associated thromboembolism
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.